CDK9 and hematopoietic and lymphoid cell neoplasm: Table 1 [46–59] provides CDK inhibition profiles for CDK9 inhibitors that have reached the clinic or have been evaluated in preclinical studies in AML and other hematologic cancers (Additional file 1: Table S1 summarizes the clinical status of other CDK9 inhibitors across a broader range of tumor types).